For example, in patients with COVID-19, the number of CD14++CD16− T lymphocytes is typically low, while CD14++CD16+ (intermediate) and CD14+CD16++ (non-classical) monocytes increase [38,39]. This evidence concerns the gene CD14 and COVID-19.